Autolus Forced To Slim Down, But Believes CAR-T Has 'Transformational' Potential
Management Reshuffle And 20% Headcount Cut
The biotech has run low on funds after a difficult pandemic year, and is banking on its next-generation CAR-T therapy.
You may also be interested in...
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Hopes rise as first four evaluable patients experienced no serious adverse events, and a sustained decline in level of key Huntington’s disease protein with the novel gene therapy product.